The company is not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the selling stockholder of such shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBRX:
- Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts
- Moleculin Biotech’s Promising Earnings Call Highlights
- Moleculin Biotech upgraded to Buy from Hold at Maxim
- Moleculin Biotech Advances Clinical Trials Amid Financial Losses
- Promising Advancements in Moleculin Biotech’s Annamycin Pivotal Trial Drive Buy Rating and $8 Price Target